These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 19715304)
1. Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction. Kawamoto SA; Thompson AD; Coleska A; Nikolovska-Coleska Z; Yi H; Wang S Biochemistry; 2009 Oct; 48(40):9534-41. PubMed ID: 19715304 [TBL] [Abstract][Full Text] [Related]
2. Crystal structure of a beta-catenin/BCL9/Tcf4 complex. Sampietro J; Dahlberg CL; Cho US; Hinds TR; Kimelman D; Xu W Mol Cell; 2006 Oct; 24(2):293-300. PubMed ID: 17052462 [TBL] [Abstract][Full Text] [Related]
3. AlphaScreen selectivity assay for β-catenin/B-cell lymphoma 9 inhibitors. Zhang M; Wisniewski JA; Ji H Anal Biochem; 2015 Jan; 469():43-53. PubMed ID: 25312469 [TBL] [Abstract][Full Text] [Related]
4. Structural basis of beta-catenin recognition by Tax-interacting protein-1. Zhang J; Yan X; Shi C; Yang X; Guo Y; Tian C; Long J; Shen Y J Mol Biol; 2008 Dec; 384(1):255-63. PubMed ID: 18835279 [TBL] [Abstract][Full Text] [Related]
5. Optimizations of a novel fluorescence polarization-based high-throughput screening assay for β-catenin/LEF1 interaction inhibitors. Chen Y; Fu Z; Li D; Yue Y; Liu X Anal Biochem; 2021 Jan; 612():113966. PubMed ID: 32956692 [TBL] [Abstract][Full Text] [Related]
6. Development of a novel fluorescence polarization-based assay for studying the β-catenin/Tcf4 interaction. Tian W; Xu Y; Han X; Duggineni S; Han X; Huang Z; An J J Biomol Screen; 2012 Apr; 17(4):530-4. PubMed ID: 22127421 [TBL] [Abstract][Full Text] [Related]
7. New homogeneous high-throughput assays for inhibitors of β-catenin/Tcf protein-protein interactions. Zhang M; Huang Z; Yu B; Ji H Anal Biochem; 2012 May; 424(1):57-63. PubMed ID: 22370279 [TBL] [Abstract][Full Text] [Related]
8. The third 20 amino acid repeat is the tightest binding site of APC for beta-catenin. Liu J; Xing Y; Hinds TR; Zheng J; Xu W J Mol Biol; 2006 Jun; 360(1):133-44. PubMed ID: 16753179 [TBL] [Abstract][Full Text] [Related]
9. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. Takada K; Zhu D; Bird GH; Sukhdeo K; Zhao JJ; Mani M; Lemieux M; Carrasco DE; Ryan J; Horst D; Fulciniti M; Munshi NC; Xu W; Kung AL; Shivdasani RA; Walensky LD; Carrasco DR Sci Transl Med; 2012 Aug; 4(148):148ra117. PubMed ID: 22914623 [TBL] [Abstract][Full Text] [Related]
10. Transfer-NMR and docking studies identify the binding of the peptide derived from activating transcription factor 4 to protein ubiquitin ligase beta-TrCP. Competition STD-NMR with beta-catenin. Pons J; Evrard-Todeschi N; Bertho G; Gharbi-Benarous J; Tanchou V; Benarous R; Girault JP Biochemistry; 2008 Jan; 47(1):14-29. PubMed ID: 18052253 [TBL] [Abstract][Full Text] [Related]
11. SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction. Fan R; He H; Yao W; Zhu Y; Zhou X; Gui M; Lu J; Xi H; Deng Z; Fan M DNA Cell Biol; 2018 Feb; 37(2):126-132. PubMed ID: 29271667 [TBL] [Abstract][Full Text] [Related]
12. Molecular plasticity of beta-catenin: new insights from single-molecule measurements and MD simulation. Ritco-Vonsovici M; Ababou A; Horton M Protein Sci; 2007 Sep; 16(9):1984-98. PubMed ID: 17660262 [TBL] [Abstract][Full Text] [Related]
13. Mechanistic insights from structural studies of beta-catenin and its binding partners. Xu W; Kimelman D J Cell Sci; 2007 Oct; 120(Pt 19):3337-44. PubMed ID: 17881495 [TBL] [Abstract][Full Text] [Related]
14. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells. El-Hage P; Petitalot A; Monsoro-Burq AH; Maczkowiak F; Driouch K; Formstecher E; Camonis J; Sabbah M; Bièche I; Lidereau R; Lallemand F Mol Cancer Res; 2015 May; 13(5):902-12. PubMed ID: 25678599 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Trosset JY; Dalvit C; Knapp S; Fasolini M; Veronesi M; Mantegani S; Gianellini LM; Catana C; Sundström M; Stouten PF; Moll JK Proteins; 2006 Jul; 64(1):60-7. PubMed ID: 16568448 [TBL] [Abstract][Full Text] [Related]
16. BCL9-2 binds Arm/beta-catenin in a Tyr142-independent manner and requires Pygopus for its function in Wg/Wnt signaling. Hoffmans R; Basler K Mech Dev; 2007 Jan; 124(1):59-67. PubMed ID: 17113272 [TBL] [Abstract][Full Text] [Related]
17. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Nikolovska-Coleska Z; Wang R; Fang X; Pan H; Tomita Y; Li P; Roller PP; Krajewski K; Saito NG; Stuckey JA; Wang S Anal Biochem; 2004 Sep; 332(2):261-73. PubMed ID: 15325294 [TBL] [Abstract][Full Text] [Related]
18. Cell-type-specific function of BCL9 involves a transcriptional activation domain that synergizes with beta-catenin. Sustmann C; Flach H; Ebert H; Eastman Q; Grosschedl R Mol Cell Biol; 2008 May; 28(10):3526-37. PubMed ID: 18347063 [TBL] [Abstract][Full Text] [Related]
19. Surface plasmon resonance imaging-based protein arrays for high-throughput screening of protein-protein interaction inhibitors. Jung SO; Ro HS; Kho BH; Shin YB; Kim MG; Chung BH Proteomics; 2005 Nov; 5(17):4427-31. PubMed ID: 16196090 [TBL] [Abstract][Full Text] [Related]
20. Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors. Zhang H; Bao Y; Liu C; Li J; Zhu D; Zhang Q Future Med Chem; 2021 May; 13(10):927-940. PubMed ID: 33849283 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]